CurrentCignaPolicy 0581

Amplitude-Modulated Radiofrequency Electromagnetic Fields Therapy

Policy Summary

PayerCigna

PolicyAmplitude-Modulated Radiofrequency Electromagnetic Fields Therapy

Policy CodePolicy 0581

Change TypeInitial Review — New policy

Effective DateJul 15, 2025

Next Review DateJun 15, 20268d

Key ActionWhen billing, providers must use the most appropriate codes as of the effective date; claims for services without covered codes under the applicable Coverage Policy will be denied as not covered.

POLICY UPDATE CHANGES

New policy statement added declaring amplitude-modulated radiofrequency electromagnetic fields therapy experimental/investigational/unproven.

1HCPCS codes listed as not covered

HDERegulatory status (TheraBionic P1)

PaucityEvidence availability

Coverage Summary & Determination

Defines Cigna's coverage position for intrabuccal, systemic amplitude-modulated radiofrequency electromagnetic fields therapy (HCPCS E0767) for cancer treatment, including coding, background, evidence summary, and Medicare coverage checks. Coverage stance: not covered (therapy considered experimental, investigational, or unproven; HCPCS E0767 listed as not covered). Status: CURRENT. Effective date: 2025-07-15; Last review: 2025-07-15; Next review: 2026-06-15.

Policy metadata

policy_number0581

policy_title/subjectAmplitude-modulated radiofrequency electromagnetic fields therapy (intrabuccal) for cancer

statusCURRENT

effective_date2025-07-15

last_review2025-07-15

next_review2026-06-15

regulatory_noteTheraBionic P1 received FDA Humanitarian Device Exemption (HDE H220001) for advanced HCC after failure of first- and second-line therapy

Medical-Necessity Criteria

Coverage Determination

Coverage position for amplitude-modulated, radiofrequency electromagnetic fields therapy:

Amplitude-modulated, radiofrequency electromagnetic fields therapy (HCPCS E0767) is considered experimental, investigational or unproven.

Coding (HCPCS)

Considered Experimental/Investigational/UnprovenHCPCSNot Covered

E0767

Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories

Billing Rule

Use appropriate codes when billing

When billing, providers must use the most appropriate codes as of the effective date. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered.

E0767

Provider Actions & Billing Guidance

Prior Authorization

Coverage requires review under plan terms

Coverage determinations require consideration of the applicable benefit plan document and related rules. Medical directors have discretion in making individual coverage determinations and must review each request on its own merits, referencing the terms of the applicable benefit plan, applicable laws/regulations, and relevant collateral materials.

Determine benefits per the applicable benefit plan document (e.g., Group Service Agreement, Evidence of Coverage, SPD).
Consider applicable federal/state laws and regulations.
Review relevant collateral source materials, including Coverage Policies and the specific facts of the situation.

Denial Risk

Denial risk — HCPCS E0767 not covered

Amplitude-modulated, radiofrequency electromagnetic fields therapy (HCPCS E0767) is considered experimental, investigational, or unproven. Services billed with HCPCS E0767 are not covered under this policy and claims will be denied as not covered.

Coverage stance: not covered (cosmetic/not medically necessary per policy).
Primary policy criterion: E0767 considered experimental/investigational/unproven (see Coverage Determination).

Background, Evidence Summary & Definitions

Low-energy amplitude-modulated radiofrequency electromagnetic fields (LEAM RF EMFs) are delivered intrabuccally using small battery-operated devices (for example, the TheraBionic P1 and the AutEMdev) that emit very low-power systemic EMFs via a spoon-shaped stainless-steel antenna placed in the mouth. These devices produce whole-body specific absorption rates far below international safety limits and are too low to cause detectable heating. The hypothesized mechanism is non-thermal modulation of electrically excitable cells that may disrupt cancer cell proliferation. Regulatory status: the TheraBionic P1 received FDA Breakthrough designation and a Humanitarian Device Exemption (HDE) approval (H220001) on September 26, 2023 for treatment of adults with advanced hepatocellular carcinoma after failure of first- and second-line therapy; the AutEMdev has not received FDA approval and is not available for commercial distribution.

Study / Source	Key findings
Costa et al. 2011 (advanced HCC feasibility)	41 patients; median PFS 4.4 months, median OS 6.7 months; 34.1% had stable disease ≥6 months; treatment well tolerated with no NCI grade 2–4 toxicities; authors recommended randomized studies
Blackstock et al. 2021	Pooled analyses including 59 patients receiving TheraBionic; median OS 6.72 months; mostly grade 1 adverse events (mucositis, fatigue); no discontinuations for adverse events
Regulatory	TheraBionic P1 received FDA Breakthrough Device designation and Humanitarian Device Exemption (HDE H220001) on September 26, 2023; AutEMdev not FDA-approved

Amplitude-modulated radiofrequency electromagnetic fields therapy: Intrabuccal, systemic delivery of low-energy amplitude-modulated radiofrequency electromagnetic fields intended for cancer treatment (HCPCS E0767).

HDE: Humanitarian Device Exemption — an FDA regulatory pathway for devices intended to treat or diagnose conditions affecting fewer than a statutory number of individuals per year; TheraBionic P1 received HDE approval (H220001) on September 26, 2023.